Cargando…
Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising after sorafenib treatment. In this study, we used...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372478/ https://www.ncbi.nlm.nih.gov/pubmed/37520282 http://dx.doi.org/10.1016/j.csbj.2023.07.005 |
_version_ | 1785078386101583872 |
---|---|
author | Zheng, Ruiqi Weng, Shuang Xu, Jianping Li, Zhuo Wang, Yaru Aizimuaji, Zulihumaer Ma, Sheng Zheng, Linlin Li, Haiyang Ying, Wantao Rong, Weiqi Xiao, Ting |
author_facet | Zheng, Ruiqi Weng, Shuang Xu, Jianping Li, Zhuo Wang, Yaru Aizimuaji, Zulihumaer Ma, Sheng Zheng, Linlin Li, Haiyang Ying, Wantao Rong, Weiqi Xiao, Ting |
author_sort | Zheng, Ruiqi |
collection | PubMed |
description | As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising after sorafenib treatment. In this study, we used proteomic techniques to explore the potential mechanisms by which pretreatment factors affect sorafenib resistance. The degree of redundant pathway PI3K/AKT activation, biotransformation capacity, and autophagy level in hepatocellular carcinoma patients prior to sorafenib treatment might affect their sensitivity to sorafenib, in which ADH1A and STING1 are key molecules. These three factors could interact mechanistically to promote tumor cell survival, might be malignant features of tumor cells, and are associated with hepatocellular carcinoma prognosis. Our study suggests possible avenues of therapeutic intervention for patients with sorafenib-resistance and the potential application of immunotherapy with the aim of improving the survival of such patients. |
format | Online Article Text |
id | pubmed-10372478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-103724782023-07-28 Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma Zheng, Ruiqi Weng, Shuang Xu, Jianping Li, Zhuo Wang, Yaru Aizimuaji, Zulihumaer Ma, Sheng Zheng, Linlin Li, Haiyang Ying, Wantao Rong, Weiqi Xiao, Ting Comput Struct Biotechnol J Research Article As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising after sorafenib treatment. In this study, we used proteomic techniques to explore the potential mechanisms by which pretreatment factors affect sorafenib resistance. The degree of redundant pathway PI3K/AKT activation, biotransformation capacity, and autophagy level in hepatocellular carcinoma patients prior to sorafenib treatment might affect their sensitivity to sorafenib, in which ADH1A and STING1 are key molecules. These three factors could interact mechanistically to promote tumor cell survival, might be malignant features of tumor cells, and are associated with hepatocellular carcinoma prognosis. Our study suggests possible avenues of therapeutic intervention for patients with sorafenib-resistance and the potential application of immunotherapy with the aim of improving the survival of such patients. Research Network of Computational and Structural Biotechnology 2023-07-05 /pmc/articles/PMC10372478/ /pubmed/37520282 http://dx.doi.org/10.1016/j.csbj.2023.07.005 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Zheng, Ruiqi Weng, Shuang Xu, Jianping Li, Zhuo Wang, Yaru Aizimuaji, Zulihumaer Ma, Sheng Zheng, Linlin Li, Haiyang Ying, Wantao Rong, Weiqi Xiao, Ting Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title | Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title_full | Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title_fullStr | Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title_full_unstemmed | Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title_short | Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
title_sort | autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372478/ https://www.ncbi.nlm.nih.gov/pubmed/37520282 http://dx.doi.org/10.1016/j.csbj.2023.07.005 |
work_keys_str_mv | AT zhengruiqi autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT wengshuang autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT xujianping autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT lizhuo autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT wangyaru autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT aizimuajizulihumaer autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT masheng autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT zhenglinlin autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT lihaiyang autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT yingwantao autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT rongweiqi autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma AT xiaoting autophagyandbiotransformationaffectsorafenibresistanceinhepatocellularcarcinoma |